Strategies to Tackle Antimicrobial Resistance: The Example of Escherichia coli and Pseudomonas aeruginosa
| Autor: | Rossella Cuffaro, Sonia Nicchi, Serena Tondi, Isabel Delany, Paolo Cinelli, Benedetta Manca, Giacomo Vezzani, Giada Antonelli, Viola Viviani, Maria Scarselli, Luigia Cappelli, Francesca Schiavetti |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.drug_class QH301-705.5 030106 microbiology Antibiotics Context (language use) Review medicine.disease_cause Catalysis Microbiology Inorganic Chemistry 03 medical and health sciences Antibiotic resistance Immune system Antigen antimicrobial resistance (AMR) vaccine Drug Resistance Bacterial Escherichia coli medicine Animals Humans Pseudomonas Infections Physical and Theoretical Chemistry Biology (General) Molecular Biology QD1-999 Escherichia coli Infections Spectroscopy outer membrane vesicles (OMV) biology Pseudomonas aeruginosa Organic Chemistry antigen identification General Medicine Antimicrobial biology.organism_classification Computer Science Applications monoclonal antibodies (mAbs) Chemistry 030104 developmental biology Bacterial Vaccines Bacteria |
| Zdroj: | International Journal of Molecular Sciences, Vol 22, Iss 4943, p 4943 (2021) International Journal of Molecular Sciences |
| ISSN: | 1661-6596 1422-0067 |
| Popis: | Traditional antimicrobial treatments consist of drugs which target different essential functions in pathogens. Nevertheless, bacteria continue to evolve new mechanisms to evade this drug-mediated killing with surprising speed on the deployment of each new drug and antibiotic worldwide, a phenomenon called antimicrobial resistance (AMR). Nowadays, AMR represents a critical health threat, for which new medical interventions are urgently needed. By 2050, it is estimated that the leading cause of death will be through untreatable AMR pathogens. Although antibiotics remain a first-line treatment, non-antibiotic therapies such as prophylactic vaccines and therapeutic monoclonal antibodies (mAbs) are increasingly interesting alternatives to limit the spread of such antibiotic resistant microorganisms. For the discovery of new vaccines and mAbs, the search for effective antigens that are able to raise protective immune responses is a challenging undertaking. In this context, outer membrane vesicles (OMV) represent a promising approach, as they recapitulate the complete antigen repertoire that occurs on the surface of Gram-negative bacteria. In this review, we present Escherichia coli and Pseudomonas aeruginosa as specific examples of key AMR threats caused by Gram-negative bacteria and we discuss the current status of mAbs and vaccine approaches under development as well as how knowledge on OMV could benefit antigen discovery strategies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|